| 15.82 0.36 (2.33%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.65 |
1-year : | 22.95 |
| Resists | First : | 16.82 |
Second : | 19.65 |
| Pivot price | 15.82 |
|||
| Supports | First : | 15.56 |
Second : | 14.78 |
| MAs | MA(5) : | 15.94  |
MA(20) : | 15.8 |
| MA(100) : | 15.7 |
MA(250) : | 15.58 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 48.3 |
D(3) : | 56.7 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 19.85 | Low : | 10.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SHC ] has closed above bottom band by 49.4%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.87 - 15.96 | 15.96 - 16.04 |
| Low: | 15.3 - 15.42 | 15.42 - 15.53 |
| Close: | 15.65 - 15.82 | 15.82 - 15.98 |
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Tue, 16 Jun 2026
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down - The Globe and Mail
Wed, 10 Jun 2026
Sotera Health (SHC) Valuation After Goldman Coverage Legal Clarity And Earnings Beat - simplywall.st
Tue, 09 Jun 2026
Geode Capital Management LLC Acquires 476,365 Shares of Sotera Health Company $SHC - MarketBeat
Mon, 08 Jun 2026
Sotera Health Company (SHC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Sun, 07 Jun 2026
Did Goldman Sachs’ Legal-Risk Reassessment Just Shift Sotera Health's (SHC) Investment Narrative? - simplywall.st
Fri, 05 Jun 2026
Goldman Sachs initiates Sotera Health stock with buy rating on durable model - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 285 (M) |
| Shares Float | 192 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 18,840 (K) |
| Shares Short P.Month | 14,250 (K) |
| EPS | 0.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.18 |
| Profit Margin | 9.9 % |
| Operating Margin | 31.2 % |
| Return on Assets (ttm) | 8.5 % |
| Return on Equity (ttm) | 22.7 % |
| Qtrly Rev. Growth | 10 % |
| Gross Profit (p.s.) | 2.3 |
| Sales Per Share | 4.17 |
| EBITDA (p.s.) | 1.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 261 (M) |
| Levered Free Cash Flow | 145 (M) |
| PE Ratio | 38.58 |
| PEG Ratio | 1.3 |
| Price to Book value | 7.25 |
| Price to Sales | 3.79 |
| Price to Cash Flow | 17.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|